O36.112
Maternal care for Anti-A sensitization, second trimester
Clinical Classification Guidelines
Medical Intelligence & Overview
Maternal care for Anti-A sensitization during the second trimester refers to specialized medical monitoring and management of pregnant women who have developed antibodies against the A blood group antigen. This condition, known medically as Anti-A sensitization, can pose risks to the fetus, including hemolytic disease, which may lead to severe anemia or other complications. Proper care during this critical period helps to understand and reduce potential harms, ensuring better outcomes for both mother and baby.
Causes & Symptoms
Clinical Causes: Previous pregnancy with an A antigen-positive fetus leading to sensitization Blood transfusions containing A antigens before pregnancy Certain medical procedures involving exposure to A antigens Lack of prior immune response controlling during previous pregnancies or transfusions
Key Symptoms: Often asymptomatic in the mother; most cases are detected through screening In rare cases, symptoms of anemia or excess fluid in the fetus In later stages, signs of fetal distress or hydrops fetalis may develop
Diagnostic & Treatment
Diagnosis Path: Diagnosis typically involves blood tests, including antibody screening and titers to detect anti-A antibodies. During routine prenatal visits, the healthcare provider may monitor antibody levels to assess risk. If antibody levels rise or reach a critical threshold, additional testing like amniocentesis or ultrasound scans are performed to evaluate fetal health and detect possible signs of hemolytic disease.
Treatment Protocols: Management of Anti-A sensitization includes close monitoring of antibody levels and fetal condition. In some cases, treatments may involve intrauterine therapy, such as transfusions, if fetal anemia is detected. After birth, the newborn may require specialized care, including phototherapy or exchange transfusions, to manage hemolytic anemia. Preventive measures, like Rh immunoglobulin, are not effective against Anti-A antibodies, so careful pregnancy management is crucial.
Clinical Advice & FAQs
Billing Guidance
Is O36.112 a billable ICD-10 code?
Yes, O36.112 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report O36.112?
Clinical documentation must specify the nature of Maternal care for Anti-A sensitization, second trimester and any associated comorbidities for accurate reporting.
Cite this Clinical Reference